ANAVEX®2-73 AD Phase 2a: Timeline and Description of the Cohort

Objective criteria for selecting patients into a clinical study who are likely to benefit from the therapy
- Minimum baseline thresholds for cognitive or functional evaluations
- Genomic biomarkers: variants in DNA which identify who will – or will not – benefit from the therapy

Anavex did a preliminary Phase 2a study with ANAVEX®2-73 to identify patient selection markers
- Study results were analyzed by Alvana Pharma using their proprietary AI KEM® platform
- The results of this analysis showed strong patient identification markers for clinical studies

Results:
- ANAVEX®2-73 improves ADL Scores (Cohen’s d) with ANAVEX®2-73 – 0.8
- Improvement of Scores in Week 57 from Baseline (Difference between groups)
- Delta MMSE (Week 57 from Baseline)
- Delta ADCS-ADL (Week 57 from Baseline)

Gene Variant Markers Improve Effect Size (Cohen’s d) with ANAVEX®2-73
A higher Cohen’s d implies less patients are needed to show a significant difference between placebo arm and ANAVEX®2-73 arm in a clinical study.

Summary
- Systematic analysis using KEM® identifies actionable parameters enabling a precision medicine approach to include best responders in follow-up Phase 2b/3 study
- Patients with a wild-type SIGMAR1 gene were found to have an improved benefit from ANAVEX®2-73. Patients with a variant of the SIGMAR1 gene were found to have a limited benefit from ANAVEX®2-73
- The minority of the population, about 20% has the variant SIGMAR1 gene, hence the majority of patients (about 80%) is expected to benefit from ANAVEX®2-73
- Gut microbiota has been collected and will be incorporated in future analysis
- The data provides support to further clinical development of ANAVEX®2-73 and further clinical studies in other indications are planned or underway
- Anavex is pioneering the use of precision medicine in CNS disorders, including Alzheimer’s disease

Full Genomic Analysis of ANAVEX®2-73 Phase 2a Alzheimer’s Disease Study Identifies Biomarkers Enabling Targeted Therapy and a Precision Medicine Approach
Harald Hampel, Prof., MD, PhD; Mohammad Afshar, MD, PhD; Frédéric Parmentier, PhD; Coralie Williams, MSc; Adrien Etcheto, MSc; Federico Goodsaal, PhD; Emmanuel O Fadrifan, PhD; Christopher U Missling, PhD;